Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression and spread of cancer.

Each personalized gene profile provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.

Sources: cancer.gov and fda.gov

ALK Fusions
Alectinib
Brigatinib
Ceritinib
Crizotinib
Lorlatinib

ATM (prostate cancer)
Olaparib

BRAF
Dabrafenib plus Trametinib
Encorafenib plus Binimetinib
Vemurafenib plus Cobimetinb

BRCA1/BRCA2
Niraparib
Olarparib
Rucaparib
Talazoparib

BARD1 (prostate cancer)
Olarparib

CDK12 (prostate cancer)
Olarparib

CHEK1 (prostate cancer)
Olarparib

CHEK2 (prostate cancer)
Olarparib

EGFR
Afatinib
Dacomitinib
Erlotinib
Gefitinib
Osimertinib

EGFR exon 20
Amivantamab
Mobocertinib

ERBB2 Gene Amplification
Ado-Trastuzumab Emtansine
Lapatinib
Margetuximab
Neratinib
Pertuzumab
Trastuzumab
Trastuzumab Deruxtecan

EZH2
Tazemetostat

FGFR2/FGFR3 Fusions
Erdafitinib
Infigratinib
Pemigatinib

IDH1
Ivosidenib

KIT
Imatinib
Regorafenib
Ripretinib
Sunitinib

KRAS G12C
Sotorasib

MET
Cabozantinib
Capmatinib
Crizotinib
Tepotinib

NF1
Selumetinib

NTRK Fusions
Entrectinib
Larotrectinib

PALB2 (prostate cancer)
Olarparib

PDGFRA
Avapritinib
Imatinib

PIK3CA
Alpelisib

RET Fusions/Mutations
Pralsetinib
Selpercatinib

ROS1 Fusions
Crizotinib
Entrectinib

SMARCB1
Tazemetostat

MSI-H
Immune Checkpoint Inhibitor

PD-L1
Immune Checkpoint Inhibitor